Download PDF
Semin Respir Crit Care Med 2004; 25(5): 523-533
DOI: 10.1055/s-2004-836144
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Microscopic Polyangiitis

Lucy Smyth1 , Gillian Gaskin1 , Charles D. Pusey1
  • 1Renal Section, Division of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom
Further Information

Publication History

Publication Date:
09 November 2004 (online)

    Permissions and Reprints

Microscopic polyangiitis is a systemic vasculitis affecting smal-l and medium-sized vessels and is characteristically associated with a focal and segmental necrotizing glomerulonephritis. It may present as a pulmonary-renal syndrome with rapidly progressive glomerulonephritis and alveolar hemorrhage, but the pattern of disease will vary according to the organ systems involved. Granulomatous disease of the upper or lower respiratory tract is not a feature, and its presence suggests the diagnosis of Wegener's granulomatosis. The etiology of the condition is unclear, but most patients have antineutrophil cytoplasm antibodies (ANCA) with specificity for either myeloperoxidase (MPO) or proteinase 3 (PR3), and there is increasing evidence that these may be pathogenic. Current treatment includes an induction phase using cyclophosphamide and steroids to attain remission, followed by a maintenance phase in which the levels of immunosuppression are gradually reduced. Azathioprine may be substituted for cyclophosphamide at 3 months. Adjunctive plasma exchange or intravenous methylprednisolone is used in the management of either or both severe renal disease and alveolar hemorrhage, and new evidence suggests that plasma exchange is more effective in recovery of renal function. Overall, 1-year survival in systemic vasculitis is around 85%, and up to 50% of patients relapse, although relapse is less common in those with MPO-ANCA. Newer therapies are being explored in an attempt to increase the efficacy and reduce the toxicity of treatment.

KEYWORDS

Systemic vasculitis - ANCA - microscopic polyangiitis

REFERENCES

  • 1 Jennette J C, Falk R J, Andrassy K et al.. Nomenclature of systemic vasculitides: proposal of an international consensus conference.  Arthritis Rheum. 1994;  37 187-192
    CrossrefPubMedGoogle Scholar
  • 2 Davson J, Ball J, Plat R. The kidney in periarteritis nodosa.  Q J Med. 1948;  67 175-202
    PubMedGoogle Scholar
  • 3 Davies D J, Moran J E, Niall J F, Ryan G B. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology?.  Br Med J (Clin Res Ed). 1982;  285 606
    CrossrefPubMedGoogle Scholar
  • 4 van der Woude F J, Rasmussen N, Lobatto S et al.. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis.  Lancet. 1985;  1 425-429
    PubMedGoogle Scholar
  • 5 Savage C O, Winearls C G, Evans D J, Rees A J, Lockwood C M. Microscopic polyarteritis: presentation, pathology and prognosis.  Q J Med. 1985;  56 467-483
    PubMedGoogle Scholar
  • 6 Falk R J, Jennette J C. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis.  N Engl J Med. 1988;  318 1651-1657
    CrossrefPubMedGoogle Scholar
  • 7 Goldschmeding R, Dolman K M, van den Ende M E, van der Meer-Gerritsen C H, Sonnenberg A, dem Borne A E. The relation of 29 kD C-ANCA antigen to proteinase 3.  APMIS Suppl. 1990;  19 26-27
    PubMedGoogle Scholar
  • 8 Niles J, McCluskey R, Ahmad M, Arnaout M A. Wegener's granulomatosis autoantigen is a novel serine proteinase.  Blood. 1989;  74 1888-1893
    PubMedGoogle Scholar
  • 9 Tervaert J W, Goldschmeding R, Elema J D et al.. Association of autoantibodies to myeloperoxidase with different forms of vasculitis. Arthritis Rheum.  1990;  33 1264-1272
    PubMedGoogle Scholar
  • 10 Franssen C, Gans R, Kallenberg C, Hageluken C, Hoorntje S. Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: distinct differences between patients with anti-proteinase 3 and anti-myeloperoxidase autoantibodies.  J Intern Med. 1998;  244 209-216
    CrossrefPubMedGoogle Scholar
  • 11 Falk R J, Nachman P H, Hogan S L, Jennette J C. ANCA glomerulonephritis and vasculitis: a Chapel Hill perspective.  Semin Nephrol. 2000;  20 233-243
    PubMedGoogle Scholar
  • 12 Watts R A, Lane S E, Bentham G, Scott D G. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom.  Arthritis Rheum. 2000;  43 414-419
    CrossrefPubMedGoogle Scholar
  • 13 Gonzalez-Gay M A, Garcia-Porrua C, Guerrero J, Rodriguez-Ledo P, Llorca J. The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions.  Arthritis Rheum. 2003;  49 388-393
    CrossrefPubMedGoogle Scholar
  • 14 Hogan S L, Satterly K K, Dooley M A, Nachman P H, Jennette J C, Falk R J. Silica exposure in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and lupus nephritis.  J Am Soc Nephrol. 2001;  12 134-142
    PubMedGoogle Scholar
  • 15 Lane S E, Watts R A, Bentham G, Innes N J, Scott D G. Are environmental factors important in primary systemic vasculitis? A case-control study.  Arthritis Rheum. 2003;  48 814-823
    CrossrefPubMedGoogle Scholar
  • 16 Dolman K M, Gans R O, Vervaat T J et al.. Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy.  Lancet. 1993;  342 651-652
    CrossrefPubMedGoogle Scholar
  • 17 Kallenberg C G, Rarok A, Stegeman C A, Limburg P C. New insights into the pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitis.  Autoimmun Rev. 2002;  1 61-66
    CrossrefPubMedGoogle Scholar
  • 18 Xiao H, Heeringa P, Hu P et al.. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice.  J Clin Invest. 2002;  110 955-963
    CrossrefPubMedGoogle Scholar
  • 19 Smyth C L, Smith J, Cook H T, Haskard D O, Pusey C D. Anti-myeloperoxidase associated pauci-immune focal segmental glomerulonephritis in rats.  Cleve Clin J Med. 2002;  69(suppl 2) 156
    PubMedGoogle Scholar
  • 20 Guillevin L, Durand-Gasselin B, Cevallos R et al.. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients.  Arthritis Rheum. 1999;  42 421-430
    CrossrefPubMedGoogle Scholar
  • 21 Hauer H A, Bajema I M, van Houwelingen H C et al.. Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups.  Kidney Int. 2002;  61 80-89
    CrossrefPubMedGoogle Scholar
  • 22 Booth A D, Almond M K, Burns A et al.. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study.  Am J Kidney Dis. 2003;  41 776-784
    CrossrefPubMedGoogle Scholar
  • 23 Franssen C F, Gans R O, Arends B et al.. Differences between anti-myeloperoxidase- and anti-proteinase 3-associated renal disease.  Kidney Int. 1995;  47 193-199
    CrossrefPubMedGoogle Scholar
  • 24 Franssen C F, Stegeman C A, Oost-Kort W W et al.. Determinants of renal outcome in anti-myeloperoxidase-associated necrotizing crescentic glomerulonephritis.  J Am Soc Nephrol. 1998;  9 1915-1923
    PubMedGoogle Scholar
  • 25 Hogan S L, Nachman P H, Wilkman A S, Jennette J C, Falk R J. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis.  J Am Soc Nephrol. 1996;  7 23-32
    PubMedGoogle Scholar
  • 26 Mistry N E, Pusey C D, Gaskin G. Markers of pulmonary haemorrhage in microscopic polyangiitis [abstract].  Sarcoidosis Vasc Diffuse Lung Dis. 1996;  13 268
    PubMedGoogle Scholar
  • 27 Eschun G M, Mink S N, Sharma S. Pulmonary interstitial fibrosis as a presenting manifestation in perinuclear antineutrophilic cytoplasmic antibody microscopic polyangiitis.  Chest. 2003;  123 297-301
    CrossrefPubMedGoogle Scholar
  • 28 Homma S, Matsushita H, Nakata K. Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitides.  Respirology. 2004;  9 190-196
    CrossrefPubMedGoogle Scholar
  • 29 Savige J, Gillis D, Benson E et al.. International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA).  Am J Clin Pathol. 1999;  111 507-513
    PubMedGoogle Scholar
  • 30 Fauci A S, Haynes B F, Katz P, Wolff S M. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years.  Ann Intern Med. 1983;  98 76-85
    CrossrefPubMedGoogle Scholar
  • 31 Jayne D, Rasmussen N, Andrassy K et al.. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.  N Engl J Med. 2003;  349 36-44
    CrossrefPubMedGoogle Scholar
  • 32 Cole E, Cattran D, Magil A et al.. A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group.  Am J Kidney Dis. 1992;  20 261-269
    PubMedGoogle Scholar
  • 33 Pusey C D, Rees A J, Evans D J, Peters D K, Lockwood C M. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies.  Kidney Int. 1991;  40 757-763
    PubMedGoogle Scholar
  • 34 Frasca G M, Soverini M L, Falaschini A, Tampieri E, Vangelista A, Stefoni S. Plasma exchange treatment improves prognosis of antineutrophil cytoplasmic antibody-associated crescentic glomerulonephritis: a case-control study in 26 patients from a single center.  Ther-Apher Dial. 2003;  7 540-546
    CrossrefPubMedGoogle Scholar
  • 35 Bolton W K, Sturgill B C. Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis.  Am J Nephrol. 1989;  9 368-375
    PubMedGoogle Scholar
  • 36 Andrassy K, Erb A, Koderisch J, Waldherr R, Ritz E. Wegener's granulomatosis with renal involvement: patient survival and correlations between initial renal function, renal histology, therapy and renal outcome.  Clin Nephrol. 1991;  35 139-147
    PubMedGoogle Scholar
  • 37 Gaskin G, Pusey C D. Plasmapheresis in antineutrophil cytoplasmic antibody-associated systemic vasculitis.  Ther Apher. 2001;  5 176-181
    PubMedGoogle Scholar
  • 38 Gaskin G, Pusey C. Long-term outcome after immunosuppression and plasma exchange for severe vasculitis-associated glomerulonephritis [abstract].  J Am Soc Nephrol. 1999;  10 101A
    PubMedGoogle Scholar
  • 39 Klemmer P J, Chalermskulrat W, Reif M S, Hogan S L, Henke D C, Falk R J. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis.  Am J Kidney Dis. 2003;  42 1149-1153
    CrossrefPubMedGoogle Scholar
  • 40 de Groot K, Adu D, Savage C O. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review.  Nephrol Dial Transplant. 2001;  16 2018-2027
    PubMedGoogle Scholar
  • 41 Nowack R, Gobel U, Klooker P, Hergesell O, Andrassy K, van der Woude F J. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement.  J Am Soc Nephrol. 1999;  10 1965-1971
    PubMedGoogle Scholar
  • 42 Jayne D R, Chapel H, Adu D et al.. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity.  QJM. 2000;  93 433-439
    CrossrefPubMedGoogle Scholar
  • 43 Richter C, Schnabel A, Csernok E, de Groot K, Reinhold-Keller E, Gross W L. Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin.  Clin Exp Immunol. 1995;  101 2-7
    PubMedGoogle Scholar
  • 44 Langford C A, Talar-Williams C, Barron K S, Sneller M C. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse.  Am J Med. 2003;  114 463-469
    CrossrefPubMedGoogle Scholar
  • 45 de Groot K, Rasmussen N, Cohen Tervaert J W, Jayne D. Randomised trial of cycophosphamide versus methotrexate for induction of remission in “non-renal” ANCA-associated vasculitis [abstract].  J Am Soc Nephrol. 2002;  13 2A
    PubMedGoogle Scholar
  • 46 Schmitt W H, Hagen E C, Neumann I, Nowack R, Flores-Suarez L F, van der Woude F J. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients.  Kidney Int. 2004;  65 1440-1448
    CrossrefPubMedGoogle Scholar
  • 47 Lockwood C M. Refractory Wegener's granulomatosis: a model for shorter immunotherapy of autoimmune diseases.  J R Coll Physicians Lond. 1998;  32 473-478
    PubMedGoogle Scholar
  • 48 Specks U, Fervenza F C, McDonald T J, Hogan M C. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy.  Arthritis Rheum. 2001;  44 2836-2840
    CrossrefPubMedGoogle Scholar
  • 49 Stone J H. Current status of tumor necrosis factor inhibition strategies in the treatment of vasculitis.  Kidney Blood Press Res. 2003;  26 240-248
    CrossrefPubMedGoogle Scholar
  • 50 Booth A, Harper L, Hammad T et al.. Prospective study of TNF alpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis.  J Am Soc Nephrol. 2004;  15 717-721
    CrossrefPubMedGoogle Scholar
  • 51 Birck R, Warnatz K, Lorenz H M et al.. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy.  J Am Soc Nephrol. 2003;  14 440-447
    CrossrefPubMedGoogle Scholar
  • 52 Allen A, Pusey C, Gaskin G. Outcome of renal replacement therapy in antineutrophil cytoplasmic antibody-associated systemic vasculitis.  J Am Soc Nephrol. 1998;  9 1258-1263
    PubMedGoogle Scholar
  • 53 Stegeman C A, Tervaert J W, van Son W J, Tegzess A M. Necrotizing glomerulonephritis associated with antimyeloperoxidase antibodies in a renal transplant recipient with renal failure of unknown origin.  Nephrol Dial Transplant. 1994;  9 839-842
    PubMedGoogle Scholar
  • 54 Elmedhem A, Adu D, Savage C O. Relapse rate and outcome of ANCA-associated small vessel vasculitis after transplantation.  Nephrol Dial Transplant. 2003;  18 1001-1004
    PubMedGoogle Scholar
  • 55 Nachman P H, Segelmark M, Westman K et al.. Recurrent ANCA-associated small vessel vasculitis after transplantation: a pooled analysis.  Kidney Int. 1999;  56 1544-1550
    CrossrefPubMedGoogle Scholar
  • 56 Gallagher H, Kwan J T, Jayne D R. Pulmonary renal syndrome: a 4-year, single-center experience.  Am J Kidney Dis. 2002;  39 42-47
    CrossrefPubMedGoogle Scholar
  • 57 Hoffman G S, Kerr G S, Leavitt R Y et al.. Wegener granulomatosis: an analysis of 158 patients.  Ann Intern Med. 1992;  116 488-498
    CrossrefPubMedGoogle Scholar
  • 58 Stillwell T J, Benson Jr R C, DeRemee R A, McDonald T J, Weiland L H. Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis.  Arthritis Rheum. 1988;  31 465-470
    PubMedGoogle Scholar
  • 59 Kamesh L, Harper L, Savage C O. ANCA-positive vasculitis.  J Am Soc Nephrol. 2002;  13 1953-1960
    CrossrefPubMedGoogle Scholar
  • 60 Bajema I M, Hagen E C, Hermans J et al.. Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis.  Kidney Int. 1999;  56 1751-1758
    CrossrefPubMedGoogle Scholar
  • 61 Hauer H A, Bajema I M, van Houwelingen H C et al.. Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients.  Kidney Int. 2002;  62 1732-1742
    CrossrefPubMedGoogle Scholar
  • 62 Jayne D, Rasmussen N, Andrassy K et al.. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.  N Engl J Med. 2003;  349 36-44
    CrossrefPubMedGoogle Scholar
  • 63 Nachman P H, Hogan S L, Jennette J C, Falk R J. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis.  J Am Soc Nephrol. 1996;  7 33-39
    PubMedGoogle Scholar
  • 64 Gaskin G, Savage C O, Ryan J J et al.. Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis.  Nephrol Dial Transplant. 1991;  6 689-694
    PubMedGoogle Scholar
  • 65 Tervaert J W, Huitema M G, Hene R J et al.. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre.  Lancet. 1990;  336 709-711
    CrossrefPubMedGoogle Scholar
  • 66 Han W K, Choi H K, Roth R M, McCluskey R T, Niles J L. Serial ANCA titers: useful tool for prevention of relapses in ANCA-associated vasculitis.  Kidney Int. 2003;  63 1079-1085
    CrossrefPubMedGoogle Scholar

Charles D PuseyF.R.C.P. 

Renal Section, Division of Medicine, Imperial College London

Hammersmith Hospital, Du Cane Rd.

London W12 0NN, UK

Email: c.pusey@imperial.ac.uk

      >